A Novel Anti-CD44 Variant 9 Monoclonal Antibody C₄₄Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers.

ABSTRACT: Cluster of differentiation 44 (CD44) is a type I transmembrane glycoprotein and has been shown to be a cell surface marker of cancer stem-like cells in various cancers. In particular, the splicing variants of CD44 (CD44v) are overexpressed in cancers and play critical roles in cancer stemness, invasiveness, and resistance to chemotherapy and radiotherapy. Therefore, the understanding of the function of each CD44v is indispensable for CD44-targeting therapy. CD44v9 contains the variant 9-encoded region, and its expression predicts poor prognosis in patients with various cancers. CD44v9 plays critical roles in the malignant progression of tumors. Therefore, CD44v9 is a promising target for cancer diagnosis and therapy. Here, we developed sensitive and specific monoclonal antibodies (mAbs) ag

SUBMITTER: Tawara M 

PROVIDER: S-EPMC10137259 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature